VANCOUVER, BRITISH COLUMBIA--(Marketwired - Dec. 4, 2013) - Sirona Biochem Corp. (TSX VENTURE:SBM)(OTCQX:SRBCF) and Bloom Burton & Co. ("Bloom Burton") announce the signing of a joint venture to conduct collaborative research to develop and commercialize new therapeutics in the areas of inflammation and infectious disease.
Sirona and Bloom Burton will identify and design numerous different anti-inflammatory and anti-infective compounds. Sirona will be responsible for the chemistry, using its proprietary expertise in fluorination technology. Bloom Burton will be responsible for financing, clinical validation and commercialization of the compounds. At present, there are unmet market needs in the areas of rare or neglected inflammatory diseases and bacterial resistance. With the former, often overlooked and the latter, an emerging threat, the collaboration between Sirona and Bloom Burton will endeavor to help minimize the medical gap by maximizing on each of the companies' core competencies.
"We are extremely excited to be working alongside Bloom Burton, a national leader in healthcare-specialized investment banking" said Neil Belenkie, CEO of Sirona Biochem. "This joint venture will combine the best of our expertise to develop the compounds, expanding our product portfolio and delivering innovative solutions in therapeutic areas with unmet needs."
"We have always appreciated the strength of Sirona's chemistry platform and we are excited to explore opportunities in two important and unmet therapeutic indications," said Brian Bloom, President of Bloom Burton & Co. "In addition to capital raising, advisory, equity research and direct investments, Bloom Burton is excited to expand its activities to include company creation and incubation, which should create value for Sirona shareholders and our firm."
About Bloom Burton & Co.
Bloom Burton & Co. exists to accelerate monetization in healthcare. Bloom Burton has an experienced team of medical, scientific, pharmaceutical, legal and capital markets professionals who perform a deeper level of diligence, which combined with a creative and entrepreneurial culture, leads to the right monetizing events for companies and investors. Bloom Burton's many services include capital raising, mergers and acquisitions advisory, equity research, scientific and medical consulting, direct investing, company creation and incubation. For more information, please visit www.bloomburton.com.
About Sirona Biochem
Sirona Biochem is not a traditional biotech company. Sirona is a product-pipeline company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are being developed for both pharmaceutical and cosmetic marketplaces and are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem's wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.